Program
ENX-104
A development code.
Its studies are mostly in Depressive Disorder, Major, led by Engrail Therapeutics.
Furthest: phase 1, since Nov 19, 20253 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Engrail Therapeutics | 30 open or running | phase 1since Nov 19, 2025 | Nov 19, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2025First studies: 2 phase 1 studiesFirst studyNCT07253324, NCT07253272
- Feb 24, 2026Phase 1 study in Healthy VolunteersNCT07472361 · 12 enrolled · United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07472361Healthy Volunteers · United Kingdom | 1 | Completed | Mar 19, 2026 | 12 |
| NCT07253324Depressive Disorder, Major · United Kingdom | 1 | Completed | Nov 26, 2025 | 48 |
| NCT07253272Healthy Volunteers · United Kingdom | 1 | Completed | Sep 2, 2025 | 10 |
How it is read
Names in the registry
- “ENX-104”, 4 entries
Codes read as this program: ENX104.
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.